Search
Contact
04.12.2024 | Deal Notifications

KPMG Law and KPMG advises Brain Biotech AG on license agreements and monetization of license rights

KPMG Law Rechtsanwaltsgesellschaft mbH and KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) advised Brain Biotech AG on the monetization of licensing rights with Royalty Pharma and the conclusion of an exclusive pharmaceutical licensing agreement for the G-dase-E®-CRISPR-Cas technology with Akribion Therapeutics.

BRAIN Biotech has entered into an agreement with Royalty Pharma for the monetization of the license rights to the investigational pharmaceutical compound deucrictibant in the amount of up to EUR 128.88 million. BRAIN Biotech will receive an upfront payment of EUR 18.41 million, additional potential regulatory milestone payments of up to EUR 18.42 million and additional potential long-term sales-related milestones of up to EUR 92.05 million. In addition, BRAIN Biotech has entered into an exclusive technology license agreement with Akribion Therapeutics GmbH for the use of the genome editing nuclease G-dase E® for the pharmaceutical sector. BRAIN Biotech will receive up to EUR 92.3 million in R&D and commercial milestone payments from Akribion for the granting of these exclusive rights for use in the pharmaceutical field. In addition, BRAIN Biotech will be entitled to royalties from future net sales. The payment structure is based on progress in clinical development and future commercialization success. KPMG Law provided comprehensive legal advice on the structuring of the transaction, including all aspects of copyright, licensing and transaction law. The accounting and tax advice as well as the comprehensive valuation of the licenses was provided by a KPMG team. Royalty Pharma was advised by an international team from Goodwin Procter. Advisor Brain Biotech AG:

KPMG Law Rechtsanwaltsgesellschaft mbH: Stefan Kimmel (Partner, Corporate/M&A, Berlin), Dr. Anna Wipper (Partner, IP/IT, Berlin) – both lead – Gunars Urdze (Senior Manager, Corporate, M&A, Cologne), Dr. Thomas Beyer (Senior Manager, IP/IT, Berlin), Isabelle Knoché (Senior Manager, Legal Financial Services, Frankfurt/Main), Christina Laux (Senior Associate , Legal Financial Services, Frankfurt/Main),; Dr. Jonas Brueckner (Partner, Antitrust and Foreign Trade Law, Berlin).

KPMG AG Wirtschaftsprüfungsgesellschaft: Christian Klingbeil (Partner, Valuation, Head of Deal Advisory Life Science, Munich), Sebastian Bongartz (Senior Manager, International Transaction Tax, Düsseldorf).

 

Explore #more

18.12.2025 | Deal Notifications

KPMG Law and KPMG advise the shareholders of Frerk Aggregatebau on the sale to DEUTZ

KPMG Law Rechtsanwaltsgesellschaft mbH (KPMG Law) and KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) provided comprehensive advice to the shareholders of Frerk Aggregatebau GmbH (Frerk) on the sale…

17.12.2025 | KPMG Law Insights

AI-supported risk checks of NDAs and CoCs: how legal departments benefit

Artificial intelligence can relieve legal departments of routine tasks such as checking non-disclosure agreements (NDAs) or codes of conduct (CoCs). These documents are part of…

16.12.2025 | In the media

Interview with KPMG Law experts: CSDDD after the omnibus: “Toothless tiger” or pragmatic solution?

The agreement on the Omnibus I package is causing discussion. Among other things, the thresholds for the EU Supply Chain Directive (CSDDD) have been significantly…

15.12.2025 | In the media

KPMG Law guest article in Tagesspiegel Background: What the digital omnibus means for companies today

The debate on the digital omnibus has only just begun. Companies should contribute their expertise to the ongoing process and strengthen their internal foundations –…

12.12.2025 | KPMG Law Insights

Focus offshore: NRW buys extensive tax data on international tax havens

According to recent press reports from December 11, 2025, the state of North Rhine-Westphalia has purchased an extensive data set with tax-relevant information from international…

12.12.2025 | Deal Notifications

KPMG Law advises The Chemours Company on the implementation and closing of a large-volume factoring financing

KPMG Law Rechtsanwaltsgesellschaft GmbH (KPMG Law) advised the US-American Chemours Company on the implementation of a cross-border factoring financing. The legal implementation was managed by…

11.12.2025 | KPMG Law Insights

First omnibus package to relax CSDDD, CSRD and EU taxonomy obligations

Negotiators from the EU Parliament and the Council have now reached an agreement on the outstanding points of the first omnibus package. The content of…

11.12.2025 | KPMG Law Insights

IPCEI-AI: Requirements for funding and evaluation criteria

On December 5, 2025, the Federal Ministry for Economic Affairs and Energy launched the expression of interest procedure for the “IPCEI Artificial Intelligence” (IPCEI-AI) funding…

11.12.2025 | In the media

Interview in TextilWirtschaft – What the relaxed EU supply chain law means for the industry

After weeks of debate, the weakened form of the CSDDD has now been adopted in Brussels. This brings new, complex legal uncertainties for companies, says…

02.12.2025 | KPMG Law Insights

Implementation of the Pay Transparency Directive: what the expert commission recommends

The EU Pay Transparency Directive has been in force since June 2023 and must now be transposed into German law. In the coalition agreement,…

© 2024 KPMG Law Rechtsanwaltsgesellschaft mbH, associated with KPMG AG Wirtschaftsprüfungsgesellschaft, a public limited company under German law and a member of the global KPMG organisation of independent member firms affiliated with KPMG International Limited, a Private English Company Limited by Guarantee. All rights reserved. For more details on the structure of KPMG’s global organisation, please visit https://home.kpmg/governance.

 KPMG International does not provide services to clients. No member firm is authorised to bind or contract KPMG International or any other member firm to any third party, just as KPMG International is not authorised to bind or contract any other member firm.

Scroll